S&P 500   4,558.33 (-0.21%)
DOW   35,985.44 (+0.10%)
QQQ   387.07 (-0.45%)
AAPL   190.15 (+0.11%)
MSFT   373.91 (-1.32%)
META   322.41 (-1.45%)
GOOGL   131.30 (-0.93%)
AMZN   146.46 (+0.25%)
TSLA   234.30 (-2.41%)
NVDA   464.72 (-0.64%)
NIO   7.05 (-3.03%)
BABA   72.90 (-2.64%)
AMD   119.14 (-1.67%)
T   16.65 (+0.48%)
F   10.35 (+0.88%)
MU   75.32 (-1.05%)
CGC   0.56 (-0.82%)
GE   122.53 (+0.60%)
DIS   92.25 (-0.47%)
AMC   6.72 (+1.05%)
PFE   28.59 (-6.17%)
PYPL   58.19 (+1.01%)
XOM   103.92 (+1.15%)
S&P 500   4,558.33 (-0.21%)
DOW   35,985.44 (+0.10%)
QQQ   387.07 (-0.45%)
AAPL   190.15 (+0.11%)
MSFT   373.91 (-1.32%)
META   322.41 (-1.45%)
GOOGL   131.30 (-0.93%)
AMZN   146.46 (+0.25%)
TSLA   234.30 (-2.41%)
NVDA   464.72 (-0.64%)
NIO   7.05 (-3.03%)
BABA   72.90 (-2.64%)
AMD   119.14 (-1.67%)
T   16.65 (+0.48%)
F   10.35 (+0.88%)
MU   75.32 (-1.05%)
CGC   0.56 (-0.82%)
GE   122.53 (+0.60%)
DIS   92.25 (-0.47%)
AMC   6.72 (+1.05%)
PFE   28.59 (-6.17%)
PYPL   58.19 (+1.01%)
XOM   103.92 (+1.15%)
S&P 500   4,558.33 (-0.21%)
DOW   35,985.44 (+0.10%)
QQQ   387.07 (-0.45%)
AAPL   190.15 (+0.11%)
MSFT   373.91 (-1.32%)
META   322.41 (-1.45%)
GOOGL   131.30 (-0.93%)
AMZN   146.46 (+0.25%)
TSLA   234.30 (-2.41%)
NVDA   464.72 (-0.64%)
NIO   7.05 (-3.03%)
BABA   72.90 (-2.64%)
AMD   119.14 (-1.67%)
T   16.65 (+0.48%)
F   10.35 (+0.88%)
MU   75.32 (-1.05%)
CGC   0.56 (-0.82%)
GE   122.53 (+0.60%)
DIS   92.25 (-0.47%)
AMC   6.72 (+1.05%)
PFE   28.59 (-6.17%)
PYPL   58.19 (+1.01%)
XOM   103.92 (+1.15%)
S&P 500   4,558.33 (-0.21%)
DOW   35,985.44 (+0.10%)
QQQ   387.07 (-0.45%)
AAPL   190.15 (+0.11%)
MSFT   373.91 (-1.32%)
META   322.41 (-1.45%)
GOOGL   131.30 (-0.93%)
AMZN   146.46 (+0.25%)
TSLA   234.30 (-2.41%)
NVDA   464.72 (-0.64%)
NIO   7.05 (-3.03%)
BABA   72.90 (-2.64%)
AMD   119.14 (-1.67%)
T   16.65 (+0.48%)
F   10.35 (+0.88%)
MU   75.32 (-1.05%)
CGC   0.56 (-0.82%)
GE   122.53 (+0.60%)
DIS   92.25 (-0.47%)
AMC   6.72 (+1.05%)
PFE   28.59 (-6.17%)
PYPL   58.19 (+1.01%)
XOM   103.92 (+1.15%)

Innoviva Stock Price, News & Analysis (NASDAQ:INVA)

$13.69
-0.16 (-1.16%)
(As of 10:15 AM ET)
Compare
Today's Range
$13.69
$13.99
50-Day Range
$12.32
$13.89
52-Week Range
$10.64
$14.08
Volume
30,024 shs
Average Volume
655,325 shs
Market Capitalization
$877.39 million
P/E Ratio
31.11
Dividend Yield
N/A
Price Target
$15.17

Innoviva MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
9.5% Upside
$15.17 Price Target
Short Interest
Bearish
15.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.33
Upright™ Environmental Score
News Sentiment
0.48mentions of Innoviva in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.33 out of 5 stars

Medical Sector

847th out of 948 stocks

Pharmaceutical Preparations Industry

413th out of 449 stocks


INVA stock logo

About Innoviva Stock (NASDAQ:INVA)

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

INVA Stock Price History

INVA Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Innoviva: A Lot Of Moving Parts
Innoviva (NASDAQ: INVA)
Innoviva's Reward Isn't Worth The Risk
Innoviva Announces Retirement of Board Chairman
See More Headlines
Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INVA
Previous Symbol
NASDAQ:THRX
CUSIP
88338T10
Employees
101
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$15.17
High Stock Price Target
$22.50
Low Stock Price Target
$10.00
Potential Upside/Downside
+9.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$213.92 million
Pretax Margin
23.49%

Debt

Sales & Book Value

Annual Sales
$331.34 million
Cash Flow
$2.35 per share
Book Value
$9.79 per share

Miscellaneous

Free Float
63,190,000
Market Cap
$887.65 million
Optionable
Optionable
Beta
0.50

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report














INVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Innoviva stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" INVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INVA, but not buy additional shares or sell existing shares.
View INVA analyst ratings
or view top-rated stocks.

What is Innoviva's stock price target for 2024?

3 brokerages have issued 12 month target prices for Innoviva's stock. Their INVA share price targets range from $10.00 to $22.50. On average, they expect the company's stock price to reach $15.17 in the next year. This suggests a possible upside of 9.5% from the stock's current price.
View analysts price targets for INVA
or view top-rated stocks among Wall Street analysts.

How have INVA shares performed in 2023?

Innoviva's stock was trading at $13.25 on January 1st, 2023. Since then, INVA shares have increased by 4.5% and is now trading at $13.85.
View the best growth stocks for 2023 here
.

Are investors shorting Innoviva?

Innoviva saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 9,610,000 shares, an increase of 7.1% from the October 31st total of 8,970,000 shares. Based on an average trading volume of 668,000 shares, the short-interest ratio is currently 14.4 days. Currently, 15.2% of the shares of the company are short sold.
View Innoviva's Short Interest
.

When is Innoviva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our INVA earnings forecast
.

How were Innoviva's earnings last quarter?

Innoviva, Inc. (NASDAQ:INVA) announced its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported $0.98 EPS for the quarter. The biotechnology company earned $67.26 million during the quarter. Innoviva had a net margin of 17.17% and a trailing twelve-month return on equity of 24.11%.

What other stocks do shareholders of Innoviva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

Who are Innoviva's major shareholders?

Innoviva's stock is owned by a variety of retail and institutional investors. Top institutional investors include Westfield Capital Management Co. LP (3.19%), Charles Schwab Investment Management Inc. (1.23%), American Century Companies Inc. (1.20%), Bank of New York Mellon Corp (1.12%), Northern Trust Corp (1.13%) and Invesco Ltd. (1.03%). Insiders that own company stock include Alexander J Denner, George Bickerstaff, Innoviva, Inc, Marianne Zhen, Pavel Raifeld and Plc Glaxosmithkline.
View institutional ownership trends
.

How do I buy shares of Innoviva?

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:INVA) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -